[go: up one dir, main page]

MXPA02000721A - Soluciones y metodos para la inhibicion del dolor, la inflamacion y la degradacion de cartilago. - Google Patents

Soluciones y metodos para la inhibicion del dolor, la inflamacion y la degradacion de cartilago.

Info

Publication number
MXPA02000721A
MXPA02000721A MXPA02000721A MXPA02000721A MXPA02000721A MX PA02000721 A MXPA02000721 A MX PA02000721A MX PA02000721 A MXPA02000721 A MX PA02000721A MX PA02000721 A MXPA02000721 A MX PA02000721A MX PA02000721 A MXPA02000721 A MX PA02000721A
Authority
MX
Mexico
Prior art keywords
pain
solutions
cartilage degradation
inflammation
methods
Prior art date
Application number
MXPA02000721A
Other languages
English (en)
Inventor
P Palmer Pamela
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MXPA02000721A publication Critical patent/MXPA02000721A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se presentan metodos y soluciones para inhibir una variedad de procesos de dolor e inflamacion en heridas de procedimientos quirurgicos generales que incluyen a los procesos artroscopicos y para inhibir la degradacion de cartilago. Las soluciones incluyen preferentemente multiples inhibidores del dolor y la inflamacion a concentracion diluida en un portador fisiologico, como por ejemplo solucion salina o solucion de Ringer lactato. La solucion puede aplicarse mediante la irrigacion continua de una herida durante un procedimiento quirurgico para la inhibicion preventiva del dolor y al tiempo que se evitan los efectos secundarios indeseables asociados con la aplicacion oral, intramuscular, subcutanea o intravenosa de mayores dosis de los agentes. Alternativamente, para combinaciones de inhibidores de la degradacion de cartilago, las soluciones pueden inyectarse directamente a la articulacion.
MXPA02000721A 1999-07-21 2000-07-21 Soluciones y metodos para la inhibicion del dolor, la inflamacion y la degradacion de cartilago. MXPA02000721A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14490499P 1999-07-21 1999-07-21
PCT/US2000/019864 WO2001007067A2 (en) 1999-07-21 2000-07-21 Solutions and methods for inhibition of pain, inflammation and cartilage degradation

Publications (1)

Publication Number Publication Date
MXPA02000721A true MXPA02000721A (es) 2004-03-10

Family

ID=22510670

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02000721A MXPA02000721A (es) 1999-07-21 2000-07-21 Soluciones y metodos para la inhibicion del dolor, la inflamacion y la degradacion de cartilago.

Country Status (13)

Country Link
EP (3) EP2322226A3 (es)
JP (2) JP2003505427A (es)
KR (2) KR20080099355A (es)
CN (2) CN1402642A (es)
AT (1) ATE399025T1 (es)
AU (1) AU779532B2 (es)
CA (2) CA2378880C (es)
DE (1) DE60039301D1 (es)
ES (1) ES2308985T3 (es)
HK (1) HK1046096B (es)
MX (1) MXPA02000721A (es)
RU (1) RU2271825C2 (es)
WO (1) WO2001007067A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
EP1875900A3 (en) * 2000-01-24 2010-07-21 Genzyme Corporation JAK/STAT pathway inhibitors and the use thereof for the treatment of osteoarthritis
ATE375797T1 (de) * 2000-09-05 2007-11-15 Meditor Pharmaceuticals Ltd Pharmazeutische zubereitungen gegen kopfschmerz, migräne, nausea und erbrechen
MXPA04003697A (es) * 2001-10-31 2005-04-08 Alcon Inc Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
MXPA04007124A (es) * 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
AU2003249317B2 (en) 2002-07-19 2007-08-02 Institute Of Materials Research And Engineering Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
SI2374819T1 (sl) 2003-05-12 2017-09-29 Helion Biotech Aps Protitelesa proteina MASP-2
DK1753456T3 (en) 2004-06-10 2016-11-28 Omeros Corp METHODS OF TREATING CONDITIONS CONNECTED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP3983272B2 (ja) * 2004-07-14 2007-09-26 有限会社 炎症研究所 腫瘍転移の抑制方法
RU2299741C1 (ru) * 2006-05-30 2007-05-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Пептид, нормализующий метаболизм в костной и хрящевой тканях, фармацевтическая композиция на его основе и способ ее применения
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
JP5306214B2 (ja) 2006-10-25 2013-10-02 リバルシオ コーポレイション 混合装置
AU2007349224B2 (en) 2006-10-25 2014-04-03 Revalesio Corporation Methods of wound care and treatment
EP2097107B1 (en) 2006-10-25 2016-05-04 Revalesio Corporation Therapeutic treatment of eyes using an oxygen-enriched solution
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
WO2008128559A1 (en) * 2007-04-20 2008-10-30 Stichting Katholieke Universiteit Method for providing a compound capable of interfering with a distorted chondrocyte phenotype
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
CN102076327B (zh) 2008-05-01 2014-04-16 利发利希奥公司 治疗消化功能紊乱的组合物和方法
EP2364154A4 (en) * 2008-10-22 2013-07-10 Revalesio Corp COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9) VEHICULAR DISEASES
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
WO2011025367A1 (en) * 2009-08-31 2011-03-03 Erasmus University Medical Center Rotterdam Method for culturing chondrocytes and uses for treatment of arthritis and chondral lesions
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
SG185133A1 (en) 2010-05-07 2012-12-28 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time
MX2013001636A (es) 2010-08-12 2013-05-01 Revalesio Corp Composiciones y metodos para el tratamiento de taupatias
PH12013501636A1 (en) * 2011-02-08 2013-10-14 Abbvie Inc Treatment of osteoarthritis and pain
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3725811A3 (en) 2011-05-04 2021-01-27 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
NZ719476A (en) 2013-10-17 2022-07-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
AU2014372575B2 (en) * 2013-12-24 2020-07-09 Ares Trading S.A FGF-18 formulation in xyloglucan gels
IL259225B (en) 2015-11-09 2022-09-01 Omeros Corp Compositions comprising masp-2 inhibitory antibodies and antigen-binding fragments thereof for use in treating tma assoiated with hematopoietic stem cell transplantation
CN105506119A (zh) * 2016-01-08 2016-04-20 张君 大鼠网膜脂肪组织炎症通路关键因子表达水平的测定方法
TW202529812A (zh) 2017-08-15 2025-08-01 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
JP7700127B2 (ja) * 2019-12-18 2025-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 疼痛及び軟骨破壊を治療するためのｇｄｆ－５変異体の使用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971955A (en) * 1981-03-02 1990-11-20 Soll David B Protection of human and animal cells during surgical trauma
US4504493A (en) 1983-07-15 1985-03-12 University Of Southern California By G. June Marshall Solution for surgical irrigation
EP0269408A3 (en) * 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5840496A (en) 1990-10-09 1998-11-24 Chiron Corporation Method for diagnosing endometrial cancer
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
JPH083058A (ja) 1994-06-17 1996-01-09 Hoechst Japan Ltd 新規な骨代謝疾患治療剤
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996013226A1 (en) * 1994-10-31 1996-05-09 Sepracor Inc. Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5591740A (en) * 1995-06-07 1997-01-07 Osteoarthritis Sciences, Incorporated Use of debromohymenialdisine for treating osteoarthritis
WO1997011692A2 (en) * 1995-09-11 1997-04-03 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
CN1215340A (zh) * 1996-02-09 1999-04-28 安姆根有限公司 包含白介素－1抑制剂和控释聚合物的组合物
US5972880A (en) * 1996-03-07 1999-10-26 Arthro Lab Inc. Method of treatment of osteoarthritis with interleuken-1 receptor antagonist
US5700774A (en) * 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
EP0949931B1 (en) * 1996-12-06 2008-08-27 Amgen Inc., Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
PT942740E (pt) * 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
RU2112495C1 (ru) * 1997-01-30 1998-06-10 Юрий Яковлевич Шмыков Способ лечения заболеваний коленного сустава
IT1291307B1 (it) * 1997-05-06 1999-01-07 Alfredo Gorio Composizione farmaceutica atta al trattamento delle patologie neurodegenerative
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
EP1261334A1 (en) * 1998-10-20 2002-12-04 Omeros Corporation Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
DE69937070D1 (de) * 1998-11-05 2007-10-18 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung

Also Published As

Publication number Publication date
HK1046096A1 (en) 2002-12-27
AU779532B2 (en) 2005-01-27
EP1797869A2 (en) 2007-06-20
EP1797869A3 (en) 2008-07-23
JP2007077165A (ja) 2007-03-29
EP2322226A3 (en) 2011-08-17
KR20020012320A (ko) 2002-02-15
CA2378880C (en) 2010-02-23
CN101850120A (zh) 2010-10-06
CN1402642A (zh) 2003-03-12
ATE399025T1 (de) 2008-07-15
RU2271825C2 (ru) 2006-03-20
WO2001007067A2 (en) 2001-02-01
ES2308985T3 (es) 2008-12-16
EP1200127B1 (en) 2008-06-25
HK1046096B (en) 2008-08-29
EP2322226A2 (en) 2011-05-18
JP2003505427A (ja) 2003-02-12
RU2002104495A (ru) 2004-03-10
CA2378880A1 (en) 2001-02-01
WO2001007067A3 (en) 2001-03-29
KR20080099355A (ko) 2008-11-12
DE60039301D1 (de) 2008-08-07
EP1200127A2 (en) 2002-05-02
CA2689694A1 (en) 2001-02-01
AU6116100A (en) 2001-02-13

Similar Documents

Publication Publication Date Title
MXPA02000721A (es) Soluciones y metodos para la inhibicion del dolor, la inflamacion y la degradacion de cartilago.
DE69229729D1 (de) Wundheilung
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
AU6397496A (en) Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO2010027830A3 (en) Methods for modulation of connective tissue growth factor expression
EP1089738A4 (en) ANTIMICROBIAL LOCKS COMPRISING DERIVATIVES OF TAURINAMIDE AND CARBOXYLIC ACIDS AND / OR THEIR SALTS
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
AU2483000A (en) Treatment of asthma with mek inhibitors
DK1009425T3 (da) Anvendelse af latens-associeret-peptid til fremstilling af et medikament til forøgelse af sårheling
IL143824A0 (en) New dialysis method
WO2000023062A3 (en) Irrigation solution and method for inhibition of pain and inflammation
DE69937070D1 (de) Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
SE9101840L (sv) Ny medicinsk anvaendning
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
WO2000023061A3 (en) Irrigation solution and method for inhibition of pain and inflammation
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
GB9904976D0 (en) Intravenous coagulation catheter for treatment of varicose veins
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
RU2002135306A (ru) Способ лечения гнойных ран
EP1563838A3 (en) Irrigation solution and method for inhibition of pain and inflammation
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
MY118982A (en) Method of reducing tissue damage associated with ischemia
ATE306923T1 (de) Verwendung von (e)-metanicotinederivate als analgetika
UA36465A (uk) Спосіб ушивання глибоких і нешироких ран та голка для його здійснення

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration